India  

New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

Video Credit: ANI - Duration: 01:21s - Published
New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

Scientists have developed a new nonsurgical treatment that decreases erranta blood flow in the shoulder to quickly reduce pain and improve function in patients with adhesive capsulitis, also known as "frozen shoulder," as per a recent research abstract.

The research abstract was presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting.

Frozen shoulder gradually causes significant pain and stiffness of the shoulder joint in an estimated 200,000 people in the U.S. each year.

The symptoms are often treated with physical therapy or pain medications until they resolve within one to three years.The research was conducted as a collaboration between interventional radiology and orthopaedic surgery to build on international studies of the procedure by adapting the treatment design and embolic agent to be more durable.

The team plans to expand the study to additional patients in 2020.

FDA-approved Investigational Device Exemption clinical trial on arterial embolization of the shoulder (AES), interventional radiologists inserted a catheter through a pinhole-sized incision in patients' wrists that was used to feed microsphere particles into as many as six arteries in the shoulder to reduce inflammation.

The treatment was conducted on an outpatient basis and took approximately one hour.

Each patient's pain, disability, and blood flow in the shoulder were measured before and after the treatment using three scales, in addition to MRI imaging to visualize the shoulder joint.The treatment was successfully completed in 16 patients whose symptoms had not responded to conservative treatment over 30 days.

The authors note that this treatment is still investigational and that conservative therapies should still be considered first.

Additionally, there are several important limitations of the research, including small sample size and lack of control arm.


You Might Like


Related videos from verified sources

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now..

Credit: Wochit Entertainment     Duration: 00:35Published
Max Minute: Hyperbaric Oxygen Treatment May Offer Less Invasive Alternative To Ventilators For COVID-19 Patients [Video]

Max Minute: Hyperbaric Oxygen Treatment May Offer Less Invasive Alternative To Ventilators For COVID-19 Patients

With COVID-19 causing severe pneumonia, doctors have been using ventilators to help their patients. CBS2's Dr. Max Gomez has more on a possible alternate treatment that's less invasive.

Credit: CBS 2 New York     Duration: 01:59Published
Study finds Hepatitis C-positive livers safe for transplantation, patients cured afterward [Video]

Study finds Hepatitis C-positive livers safe for transplantation, patients cured afterward

Patients who received a transplanted liver infected with hepatitis C and were later treated for the infection performed as well in recovery as transplant patients who received an organ free of..

Credit: ANI     Duration: 01:13Published